Bivatuzumab mertansine
Source: Wikipedia, the free encyclopedia.
Chemical compound
This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources. Find sources: "Bivatuzumab mertansine" – news · newspapers · books · scholar · JSTOR (August 2014) |
Humanized (from mouse) | |
Target | CD44 v6 |
---|---|
Clinical data | |
ATC code |
|
Identifiers | |
ChemSpider |
|
NY (what is this?) (verify) |
Bivatuzumab mertansine is a combination of
squamous cell carcinoma.[1]
References
- PMID 17062682.
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
drug article is a stub. You can help Wikipedia by expanding it. |